8-K: Allurion Technologies Secures $6.1 Million to Advance GLP-1 Clinical Pipeline

Sentiment:

8-K Filing 21 February 2025 4:06 PM

📋All filings for Allurion Technologies, INC

Allurion Technologies has successfully raised approximately $6.1 million through an offering and concurrent private placement to support its clinical pipeline focused on GLP-1 therapies.

Delay expectedThere is no guarantee we will be able to hold the special meeting by such date, or at all.If we do not obtain such stockholder approval at the special meeting, we are obligated to call a meeting every sixty days thereafter to seek such stockholder approvals until the earlier of the date on which such stockholder approval is obtained or the common warrants are no longer outstanding.The Company must use commercially reasonable efforts to have such registration statement declared effective by the SEC as soon as practicable, but in no event later than the date which shall be either (a) in the event that the SEC does not review such registration statement, 90 days after the closing date of the Leavitt Private Placement, or (b) in the event that the SEC reviews such registration statement, 120 days after such closing date (but in any event, no later than three business days following the SEC indicating that it has no further comments on the registration statement).

Capital raiseAllurion Technologies, Inc. (the Company or Allurion) entered into a securities purchase agreement (the Securities Purchase Agreement) with certain accredited investors named therein, pursuant to which the Company agreed to issue and sell 900,000 shares of the Companys common stock, par value $0.0001 per share (the Common Stock) (the Offering), and 1,800,000 accompanying common warrants (the Common Warrants) to purchase up to 1,800,000 shares of Common Stock upon exercise of the Common Warrants in a concurrent private placement (the Private Placement), at an offering price of $5.23 per share and accompanying Common Warrant.The Offering and Private Placement resulted in gross proceeds to the Company of approximately $4.7 million, before deducting the Placement Agent fees and commissions and estimated offering expenses payable by the Company.On February 19, 2025, the Company entered into a subscription agreement (the Subscription Agreement) with an accredited investor affiliated with Leavitt Equity Partners (Leavitt), pursuant to which the Company agreed to sell to Leavitt 267,686 shares of Common Stock (the Private Placement Shares) and common warrants to purchase up to 535,372 shares of Common Stock (the Private Placement Warrants and together with the Private Placement Shares, the Private Placement Securities), for an aggregate purchase price of approximately $1.4 million at a purchase price of $5.23 per share and accompanying Private Placement Warrant (the Leavitt Private Placement and together with the Private Placement, the Private Placements).

Summary

Allurion Technologies, Inc. has secured approximately $6.1 million in gross proceeds through a registered direct offering and concurrent private placement.
The offering involved the sale of 900,000 shares of common stock at $5.23 per share, along with warrants to purchase up to 1,800,000 shares.
A concurrent private placement with Leavitt Equity Partners included 267,686 shares and warrants for 535,372 shares, also at $5.23 per share and warrant.
Roth Capital Partners acted as the exclusive placement agent.
The company intends to use the net proceeds to fund clinical trials combining the Allurion Balloon with GLP-1 therapy, as well as for working capital and general corporate purposes.
The offering closed on February 20, 2025, following customary closing conditions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has successfully raised capital, which will support its clinical pipeline and growth initiatives. However, there are risks associated with clinical trials, regulatory approvals, and competition.

Positives

The capital raise will support clinical trials testing the combination of the Allurion Balloon and GLP-1 therapy.
The funds will also be used for working capital and general corporate purposes, providing financial flexibility.
The involvement of Roth Capital Partners as placement agent adds credibility to the offering.
Leavitt Equity Partners' participation demonstrates investor confidence in Allurion's strategy.

Negatives

The offering involves the issuance of new shares, which may dilute existing shareholders' equity.
The warrants, if exercised, could further dilute existing shareholders' equity.
The company needs to obtain stockholder approval for the warrants to become exercisable.

Risks

The company's clinical trials may not be successful.
The company may not be able to obtain regulatory approval for its products.
The company faces competition from other weight-loss therapies, including GLP-1 drugs.
The company's business is subject to economic downturns and a changing regulatory landscape.
The company may not be able to maintain its listing on the NYSE.

Future Outlook

The company intends to use the net proceeds from the offering and concurrent private placement to fund its clinical pipeline testing the effects of the combination of the Allurion Balloon and GLP-1 therapy on muscle mass and long-term GLP-1 adherence, for working capital, and for general corporate purposes.

Management Comments

We are pleased to be raising this financing to support key initiatives at Allurion, including our pipeline of clinical trials related to GLP-1s, said Dr. Shantanu Gaur, Founder & CEO of Allurion.
We believe that we can make GLP-1s a more effective, long-term therapy in combination with the Allurion Balloon.

Industry Context

The announcement highlights Allurion's strategic focus on combining its Allurion Balloon technology with GLP-1 therapies, reflecting a broader trend in the obesity treatment market towards combination therapies and personalized approaches.

Comparison to Industry Standards

Comparable companies in the medical device and weight loss sectors, such as ResMed, Intuitive Surgical, and Novo Nordisk, often pursue similar funding strategies to support clinical trials and product development.
The $6.1 million capital raise is relatively small compared to larger financings in the pharmaceutical industry, but it is significant for a company of Allurion's size and stage.
The use of proceeds for clinical trials and working capital is consistent with industry norms for companies in the growth phase.

Stakeholder Impact

Shareholders may experience dilution due to the issuance of new shares and warrants.
Employees may benefit from the company's increased financial stability and growth prospects.
Customers may benefit from the development of new and improved weight-loss therapies.
Suppliers and creditors may benefit from the company's increased financial stability.

Next Steps

The company will use the proceeds to fund clinical trials and for working capital.
The company will seek stockholder approval for the warrants.
The company will file a resale registration statement for the securities issued to Leavitt Equity Partners.
The company will continue to comply with reporting requirements under the Exchange Act.

Key Dates

Date	Description
2024-07	Leavitt Equity Partners issued warrants to purchase Common Stock.
2024-12-10	Initial filing date of the Registration Statement on Form S-3 (File No. 333-283721).
2024-12-20	Effective date of the Registration Statement.
2025-02-19	Date of the Securities Purchase Agreement and Subscription Agreement.
2025-02-20	Expected closing date of the offering and private placement.
2025-02-20	Filing date of the prospectus supplement.
2025-02-21	Date of the legal opinion of Goodwin Procter LLP.
2025-03-28	Target date for special meeting of stockholders to obtain Stockholder Approval.
2025-04-07	Deadline for filing a resale registration statement with the SEC to register the resale of the Private Placement Securities.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.